Shots:

• The P-III HELP OLE study evaluating the safety & efficacy of Takhzyro (300mg- q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5 yrs.
• Results: 87.4% mean reduction in attack rate compared to baseline & median reduction was 97.7%. Additionally- @70 day steady-state- attack rates were further reduced to a mean of 92.4% & median reduction of 98.2%- 83.7% & 70% patients showed maximum attack-free period after 70 day ≥ 6mos. & ≥ 12mos. respectively
• The therapy was well-tolerated & effectively reduced attack rates over an extended treatment period across subgroups of patients with HAE & safety profile was comparable across all evaluated subgroups with treatment related TEAEs

 Ref: Takeda | Image: Takeda